Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Robach, P, Gammella, E, Recalcati, S, Girelli, D, Castagna, A, Roustit, M, Lundby, C, Lundby, A-K, Bouzat, P, Vergès, S, Séchaud, G, Banco, P, Uhr, M, Cornu, C, Sallet, P & Cairo, G 2021, 'Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure', Haematologica, bind 106, nr. 2, s. 384-390. https://doi.org/10.3324/haematol.2019.233874

APA

Robach, P., Gammella, E., Recalcati, S., Girelli, D., Castagna, A., Roustit, M., Lundby, C., Lundby, A-K., Bouzat, P., Vergès, S., Séchaud, G., Banco, P., Uhr, M., Cornu, C., Sallet, P., & Cairo, G. (2021). Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure. Haematologica, 106(2), 384-390. https://doi.org/10.3324/haematol.2019.233874

CBE

Robach P, Gammella E, Recalcati S, Girelli D, Castagna A, Roustit M, Lundby C, Lundby A-K, Bouzat P, Vergès S, Séchaud G, Banco P, Uhr M, Cornu C, Sallet P, Cairo G. 2021. Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure. Haematologica. 106(2):384-390. https://doi.org/10.3324/haematol.2019.233874

MLA

Vancouver

Author

Robach, Paul ; Gammella, Elena ; Recalcati, Stefania ; Girelli, Domenico ; Castagna, Annalisa ; Roustit, Matthieu ; Lundby, Carsten ; Lundby, Anne-Kristine ; Bouzat, Pierre ; Vergès, Samuel ; Séchaud, Guillaume ; Banco, Pierluigi ; Uhr, Mario ; Cornu, Catherine ; Sallet, Pierre ; Cairo, Gaetano. / Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure. I: Haematologica. 2021 ; Bind 106, Nr. 2. s. 384-390.

Bibtex

@article{5dbe6ecf3a16448d9ab1cf122221b5f7,
title = "Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure",
abstract = "The erythropoietin (Epo)-erythroferrone (ERFE)-hepcidin axis coordinates erythropoiesis and iron homeostasis. While mouse studies have established that Epo-induced ERFE production represses hepcidin synthesis by inhibiting hepatic BMP/SMAD signaling, evidence for the role of ERFE in humans is limited. To investigate the role of ERFE as a physiological erythroid regulator in humans, we conducted two studies: first, 24 males received six injections of saline (placebo), recombinant Epo (rhEpo) 20 UI kg-1 (micro-dose) or 50 UI kg-1 (low-dose). Second, we quantified ERFE in 22 subjects exposed to high altitude (3800 m) for 15 hours. In the first study, total hemoglobin mass (Hbmass) increased after low- but not after micro-dose injections, when compared to placebo. Serum ERFE levels were enhanced by rhEpo, remaining higher than after placebo for 48 (micro-dose) or 72 hours (low-dose) post-injections. Conversely, hepcidin levels decreased when Epo and ERFE arose, before any changes in serum iron parameters occurred. In the second study, serum Epo and ERFE increased at high altitude. The present results demonstrate that in healthy humans ERFE responds to slightly increased Epo levels not associated with Hbmass expansion and down-regulates hepcidin in an apparently iron-independent way. Notably, ERFE flags micro-dose Epo, thus holding promise as novel anti-doping biomarker.",
author = "Paul Robach and Elena Gammella and Stefania Recalcati and Domenico Girelli and Annalisa Castagna and Matthieu Roustit and Carsten Lundby and Anne-Kristine Lundby and Pierre Bouzat and Samuel Verg{\`e}s and Guillaume S{\'e}chaud and Pierluigi Banco and Mario Uhr and Catherine Cornu and Pierre Sallet and Gaetano Cairo",
note = "Copyright {\textcopyright} 2020, Ferrata Storti Foundation.",
year = "2021",
month = feb,
day = "1",
doi = "10.3324/haematol.2019.233874",
language = "English",
volume = "106",
pages = "384--390",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Fondazione/Ferrata Storti",
number = "2",

}

RIS

TY - JOUR

T1 - Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure

AU - Robach, Paul

AU - Gammella, Elena

AU - Recalcati, Stefania

AU - Girelli, Domenico

AU - Castagna, Annalisa

AU - Roustit, Matthieu

AU - Lundby, Carsten

AU - Lundby, Anne-Kristine

AU - Bouzat, Pierre

AU - Vergès, Samuel

AU - Séchaud, Guillaume

AU - Banco, Pierluigi

AU - Uhr, Mario

AU - Cornu, Catherine

AU - Sallet, Pierre

AU - Cairo, Gaetano

N1 - Copyright © 2020, Ferrata Storti Foundation.

PY - 2021/2/1

Y1 - 2021/2/1

N2 - The erythropoietin (Epo)-erythroferrone (ERFE)-hepcidin axis coordinates erythropoiesis and iron homeostasis. While mouse studies have established that Epo-induced ERFE production represses hepcidin synthesis by inhibiting hepatic BMP/SMAD signaling, evidence for the role of ERFE in humans is limited. To investigate the role of ERFE as a physiological erythroid regulator in humans, we conducted two studies: first, 24 males received six injections of saline (placebo), recombinant Epo (rhEpo) 20 UI kg-1 (micro-dose) or 50 UI kg-1 (low-dose). Second, we quantified ERFE in 22 subjects exposed to high altitude (3800 m) for 15 hours. In the first study, total hemoglobin mass (Hbmass) increased after low- but not after micro-dose injections, when compared to placebo. Serum ERFE levels were enhanced by rhEpo, remaining higher than after placebo for 48 (micro-dose) or 72 hours (low-dose) post-injections. Conversely, hepcidin levels decreased when Epo and ERFE arose, before any changes in serum iron parameters occurred. In the second study, serum Epo and ERFE increased at high altitude. The present results demonstrate that in healthy humans ERFE responds to slightly increased Epo levels not associated with Hbmass expansion and down-regulates hepcidin in an apparently iron-independent way. Notably, ERFE flags micro-dose Epo, thus holding promise as novel anti-doping biomarker.

AB - The erythropoietin (Epo)-erythroferrone (ERFE)-hepcidin axis coordinates erythropoiesis and iron homeostasis. While mouse studies have established that Epo-induced ERFE production represses hepcidin synthesis by inhibiting hepatic BMP/SMAD signaling, evidence for the role of ERFE in humans is limited. To investigate the role of ERFE as a physiological erythroid regulator in humans, we conducted two studies: first, 24 males received six injections of saline (placebo), recombinant Epo (rhEpo) 20 UI kg-1 (micro-dose) or 50 UI kg-1 (low-dose). Second, we quantified ERFE in 22 subjects exposed to high altitude (3800 m) for 15 hours. In the first study, total hemoglobin mass (Hbmass) increased after low- but not after micro-dose injections, when compared to placebo. Serum ERFE levels were enhanced by rhEpo, remaining higher than after placebo for 48 (micro-dose) or 72 hours (low-dose) post-injections. Conversely, hepcidin levels decreased when Epo and ERFE arose, before any changes in serum iron parameters occurred. In the second study, serum Epo and ERFE increased at high altitude. The present results demonstrate that in healthy humans ERFE responds to slightly increased Epo levels not associated with Hbmass expansion and down-regulates hepcidin in an apparently iron-independent way. Notably, ERFE flags micro-dose Epo, thus holding promise as novel anti-doping biomarker.

UR - http://www.scopus.com/inward/record.url?scp=85086481160&partnerID=8YFLogxK

U2 - 10.3324/haematol.2019.233874

DO - 10.3324/haematol.2019.233874

M3 - Journal article

C2 - 31919080

VL - 106

SP - 384

EP - 390

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -

ID: 61782012